Comparative Effectiveness of Mineralocorticoid Receptor Antagonists in Cardiovascular, Renal and Metabolic Disease - PubMed
4 hours ago
- #mineralocorticoid receptor antagonists
- #cardiorenometabolic disease
- #real-world study
- Finerenone significantly reduces heart failure events in both HFrEF and HFpEF compared to steroidal MRAs, but with a trend of increased hyperkalemia risk in these groups.
- In CKD, DM, and non-DM cohorts, finerenone shows comprehensive superiority over steroidal MRAs, reducing risks of death and cardiovascular events, along with lower risks of AKI and hyperkalemia in some phenotypes.
- Steroidal MRAs may offer a favorable efficacy-safety balance in heart failure, while finerenone is superior for cardiorenal protection in CKD and metabolic diseases, supporting phenotype-specific MRA selection pending further research.